Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sanofi-aventis signs licensing agreement for Wellstat's insulin sensitizer PN-2034

Oct. 23, 2009

First patient enrolled in Genzyme's phase III trial of Genz-112638 in Gaucher disease

Oct. 22, 2009

Shire to file BLA for Replagal for Fabry disease by year end

Oct. 22, 2009

BioSante reports phase III LibiGel safety data

Oct. 22, 2009

Sanofi-aventis claims SGLT-2 inhibitors for the treatment of type 1 and type 2 diabetes

Oct. 21, 2009

FDA issues complete response letter regarding Endo's Fortesta NDA for hypogonadism

Oct. 21, 2009

Estradiol valerate/dienogest reduces heavy/prolonged menstrual bleeding

Oct. 21, 2009

FDA issues complete response letter regarding Amgen's BLA for Prolia

Oct. 21, 2009

Diabetes candidate drug DSP-7238 shows selective and sustained DPP IV inhibition

Oct. 20, 2009

GnRH antagonist elagolix sodium improves endometriosis symptoms in Petal study

Oct. 20, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Researchers hit back after colleagues removed from ADA meeting
BioWorld
Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an...